CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms

Essential thrombocytosis

A Study Designed to Assess the Efficacy, Safety, and Tolerability of P1101 After the 12 Month Core Treatment Period in Patients With ET. Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Childhood Essential Thrombocythemia Anagrelide vs. Hydroxyurea – Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia Anagrelide Retard vs. Placebo: Efficacy and Safety in “At-risk” Patients With Essential Thrombocythaemia Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia Anagre Cap. in Patients With High-Risk Essential Thrombocythemia French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia IMG-7289 in Patients With Essential Thrombocythemia Anagrelide Retard in Essential Thrombocythemia